Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:cosmetic
go back to main search page
Accession:CHEBI:64857 term browser browse the term
Definition:The role played by a substance in enhancing the appearance or odour of the human body; a name given to the substance itself or to a component of it.
Synonyms:related_synonym: cosmetic component;   cosmetics
 xref: Wikipedia:Cosmetics



show annotations for term's descendants           Sort by:
 
glutathione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G IDH2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions EXP Glutathione inhibits the reaction [Cadmium Chloride results in decreased activity of IDH2 protein]; Glutathione inhibits the reaction [Cadmium results in decreased activity of IDH2 protein] CTD PMID:16785314 NCBI chr 7:55,654,298...55,675,571
Ensembl chr 7:55,651,606...55,681,426
JBrowse link
G LOC100739508 glutathione S-transferase P-like multiple interactions EXP GSTP1 protein affects the metabolism of [monobromobimane co-treated with Glutathione] CTD PMID:14573868 NCBI chr 2:5,005,498...5,009,247 JBrowse link
L-ascorbic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALPL alkaline phosphatase, biomineralization associated multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA CTD PMID:30481989 NCBI chr 6:79,589,695...79,649,646
Ensembl chr 6:79,588,659...79,649,648
JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BCL2L1 mRNA CTD PMID:30481989 NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,141...35,415,359
JBrowse link
G CASP3 caspase 3 multiple interactions EXP [Troglitazone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CASP3 mRNA CTD PMID:30481989 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CEBPA CCAAT enhancer binding protein alpha multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA] CTD PMID:30481989 NCBI chr 6:43,083,200...43,085,884
Ensembl chr 6:43,083,203...43,085,836
JBrowse link
G COL1A1 collagen type I alpha 1 chain multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA CTD PMID:30481989 NCBI chr12:26,379,087...26,397,180
Ensembl chr12:26,379,090...26,397,003
JBrowse link
G CTNNB1 catenin beta 1 multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA] CTD PMID:30481989 NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,137,173...25,208,311
JBrowse link
G FABP4 fatty acid binding protein 4, adipocyte multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA] CTD PMID:30481989 NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,897
JBrowse link
G IGF1 insulin like growth factor 1 multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA] CTD PMID:30481989 NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,037
JBrowse link
G IGF1R insulin like growth factor 1 receptor multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA] CTD PMID:30481989 NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,925...137,690,666
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA] CTD PMID:30481989 NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,655...68,433,947
JBrowse link
G RUNX2 RUNX family transcription factor 2 multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA CTD PMID:30481989 NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,513...40,459,686
JBrowse link
G SPP1 secreted phosphoprotein 1 multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA] CTD PMID:30481989 NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
JBrowse link
S-nitrosoglutathione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AKT1 AKT serine/threonine kinase 1 multiple interactions EXP AKT1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein] CTD PMID:11514583
G HIF1A hypoxia inducible factor 1 subunit alpha multiple interactions
increases expression
EXP 2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; AKT1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Genistein inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; PIK3R1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Wortmannin inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein] CTD PMID:11514583 NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,181...190,674,850
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP PIK3R1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein] CTD PMID:11514583 NCBI chr16:46,434,757...46,523,626
Ensembl chr16:46,434,873...46,523,609
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 939
    role 878
      application 707
        cosmetic 17
          (Z)-non-6-en-1-ol 0
          N-carbamoyl-L-cysteine 0
          antimicrobial cosmetic preservative + 0
          dodecan-1-ol + 0
          nerolidol + 0
          palmityl acetate 0
          quaternium-52 0
          raspberry ketone 0
          skin lightening agent + 17
          stearyl palmitate 0
paths to the root